Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren (PTC124) in nonsense-mutation cystic fibrosis
NCT00234663Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ataluren in cystic fibrosis (CF), sponsored by PTC Therapeutics, Inc. Primary endpoint: Nasal Transepithelial Potential Difference. Started Sep 2005; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00234663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234663.